Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Shah

Showing results (61-70 of 119) with videos related to

Pageof 12
Sort By:
Scientific Reports|October 1, 2015
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistanceMeenu Kesarwani, Erika Huber, Zachary Kincaid, et al.
Elife|December 23, 2014
Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapyAlexander A Warkentin, Michael S Lopez, Elisabeth A Lasater, et al.
Haematologica|August 11, 2018
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemiaTimothy P Hughes, Pierre Laneuville, Philippe Rousselot, et al.
Cancer Research|July 5, 2019
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KITBeth Apsel Winger, Wilian A Cortopassi, Diego Garrido Ruiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients TrialJorge E Cortes, Giuseppe Saglio, Hagop M Kantarjian, et al.
Leukemia Research|December 31, 2013
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitorSrdan Verstovsek, Constantine S Tam, Martha Wadleigh, et al.
Blood|February 27, 2014
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 studyNeil P Shah, François Guilhot, Jorge E Cortes, et al.
Haematologica|May 17, 2020
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia modelsRaghuveer Singh Mali, Qi Zhang, Rosa Anna DeFilippis, et al.
Blood|April 21, 2024
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminibAriel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, et al.
Cancer Chemotherapy and Pharmacology|April 24, 2013
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesDaryl Sonnichsen, David J Dorer, Jorge Cortes, et al.
Pageof 12

Showing results (61-70 of 119) with videos related to

Sort By:
Pageof 12
Scientific Reports|October 1, 2015
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistanceMeenu Kesarwani, Erika Huber, Zachary Kincaid, et al.
Elife|December 23, 2014
Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapyAlexander A Warkentin, Michael S Lopez, Elisabeth A Lasater, et al.
Haematologica|August 11, 2018
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemiaTimothy P Hughes, Pierre Laneuville, Philippe Rousselot, et al.
Cancer Research|July 5, 2019
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KITBeth Apsel Winger, Wilian A Cortopassi, Diego Garrido Ruiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients TrialJorge E Cortes, Giuseppe Saglio, Hagop M Kantarjian, et al.
Leukemia Research|December 31, 2013
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitorSrdan Verstovsek, Constantine S Tam, Martha Wadleigh, et al.
Blood|February 27, 2014
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 studyNeil P Shah, François Guilhot, Jorge E Cortes, et al.
Haematologica|May 17, 2020
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia modelsRaghuveer Singh Mali, Qi Zhang, Rosa Anna DeFilippis, et al.
Blood|April 21, 2024
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminibAriel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, et al.
Cancer Chemotherapy and Pharmacology|April 24, 2013
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesDaryl Sonnichsen, David J Dorer, Jorge Cortes, et al.
Pageof 12